<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3166">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04322396</url>
  </required_header>
  <id_info>
    <org_study_id>KronLungesyg_COVID_19_protokol</org_study_id>
    <nct_id>NCT04322396</nct_id>
  </id_info>
  <brief_title>Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19</brief_title>
  <acronym>ProPAC-COVID</acronym>
  <official_title>Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID: A Randomized, Placebo-controlled Double-blinded Trial Evaluating Treatment With Azithromycin and Hydroxychloroquine to Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chronic Obstructive Pulmonary Disease Trial Network, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chronic Obstructive Pulmonary Disease Trial Network, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study explores whether patients acutely hospitalized may have shorter hospitalization&#xD;
      and fewer admittances at Intensive Care Units by treatment with azithromycin and&#xD;
      hydroxychloroquine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the ongoing coronavirus pandemic, COVID-19, that arose in Wuhan China, there is still&#xD;
      sparse data in the course, risk of various complications, and in particular how patients who&#xD;
      are hospitalized are best treated to ensure high survival and short hospitalization. Despite&#xD;
      the rapid spread of the disease globally, there is no solid data yet to recommend any&#xD;
      specific treatments, which is why symptomatic, organ supportive therapy including respiratory&#xD;
      therapy in acute pulmonary failure is recommended. There has been reported a high incidence&#xD;
      of bacterial super-infections in patients with COVID-19. Patients with COVID-19 also have a&#xD;
      higher risk of dying because of septic shock. Thus, there is an urgent need for treatment&#xD;
      that can improve the patient's chance of the shortest hospitalization possible, and treatment&#xD;
      that can lower the risk of secondary infection and death.&#xD;
&#xD;
      This is a randomized, placebo-controlled, double-blinded multi-center trial evaluating the&#xD;
      effect of azithromycin and hydroxychloroquine treatment in patients with COVID-19 during&#xD;
      hospitalization. The aim of the study is to investigate whether the treatment can shorten&#xD;
      hospitalization, reduce the risk of non-invasive ventilation, admittance to Intensive Care&#xD;
      Units and death.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 6, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of days alive and discharged from hospital within 14 days</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Categorization of hospitalization status</measure>
    <time_frame>14 days</time_frame>
    <description>The patient will becategorized into one of the following 8 categories depending on status of their hospitalization:&#xD;
Dead (yes/no)&#xD;
Hospitalized and receiving mechanical ventilation or ExtraCorporalMembraneOxygenation (ECMO) (yes/no)&#xD;
Hospitalized and receiving Non-invasive ventilation or &quot;high-flow oxygen device&quot; (yes/no)&#xD;
Hospitalized and given oxygen supplements different from (2) and (3) (yes/no)&#xD;
Hospitalized and without oxygen treatment, but receiving other treatment (both related to COVID-19 or other) (yes/no)&#xD;
Hospitalized for observation (yes/no)&#xD;
Discharged from hospital with restriction of activity level (yes/no)&#xD;
Discharged from hospital without any restrictions of activity level (yes/no)&#xD;
Only one category can be &quot;yes&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admitted to intensive care unit, if admitted to ICU then length of stay</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Have used Non-invasive ventilation (NIV) during hospitalization</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive and discharged from hospital</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of readmissions (all causes)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days using non-invasive ventilation (NIV)</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient's oxygen partial pressure</measure>
    <time_frame>4 days</time_frame>
    <description>Delta PaO2 measured in arterial puncture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient's carbondioxid partial pressure</measure>
    <time_frame>4 days</time_frame>
    <description>Delta PaCO2 measured in arterial puncture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of pH in blood</measure>
    <time_frame>4 days</time_frame>
    <description>pH measured in arterial puncture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for no oxygen supplement (or regular oxygen supplement &quot;LTOT&quot;)</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">226</enrollment>
  <condition>Virus Diseases</condition>
  <condition>Infection Viral</condition>
  <condition>Corona Virus Infection</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm will receive standard care and placebo in 15 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will receive standard care and azithromycin and hydroxychloroquine in 15 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Azithromycin</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Hydroxychloroquine</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo Azithromycin</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo Hydroxychloroquine</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient admitted to a Danish emergency department, lung medical department or medical&#xD;
             department&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Hospitalized &lt;48 hours&#xD;
&#xD;
          -  Positive COVID-19 test/diagnosis during the hospitalization&#xD;
&#xD;
          -  Signes informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  If the patient uses &gt; 5 LO2/min at time of recruitment&#xD;
&#xD;
          -  Known intolerance/allergy to azithromycin or hydroxychloroquine or hypersensitivity to&#xD;
             quinine or 4-aminoquinolinderivates&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breatfeeding&#xD;
&#xD;
          -  Neurogenic hearing loss&#xD;
&#xD;
          -  Psoriasis&#xD;
&#xD;
          -  Retinopathy&#xD;
&#xD;
          -  Maculopathy&#xD;
&#xD;
          -  Changes in vision field&#xD;
&#xD;
          -  Severe liver disease other than amoebiases&#xD;
&#xD;
          -  Severe gastrointestinal, neurological or haematological disorders&#xD;
&#xD;
          -  eGFR &lt; 45 ml/min/1.73m2&#xD;
&#xD;
          -  Clinically significant cardiac conduction disorders/arrhytmias or prolonged QTc&#xD;
             interval&#xD;
&#xD;
          -  Myasthenia Gravis&#xD;
&#xD;
          -  Uses Digoxin&#xD;
&#xD;
          -  Glucose-6-phosphate dehydrogenase defiency&#xD;
&#xD;
          -  Porphyria&#xD;
&#xD;
          -  Hypoglycemia at any time since hospitalization&#xD;
&#xD;
          -  Severe mental illness which significantly impedes cooperation&#xD;
&#xD;
          -  Severe linguistic problems that significantly impedes cooperation&#xD;
&#xD;
          -  Treatment with sickle alkaloids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jens-Ulrik Stæhr Jensen, MD, PhD</last_name>
    <phone>004528938168</phone>
    <email>jens.ulrik.jensen@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aalborg Sygehus</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulla Weinreich</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Therese Lapperre</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev-Gentofte Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens-Ulrik Jensen, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Ulrik</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nordsjællands Hospital</name>
      <address>
        <city>Hillerød</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Browatzki</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Laursen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roskilde Sygehus</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Meyer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Slagelse Sygehus</name>
      <address>
        <city>Slagelse</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uffe Bødtger</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

